ORA YOGU 4X label centers on short-term oral pain relief and a serious anesthetic risk
DailyMed’s updated label for ORA YOGU 4X Medicated Tooth and Gum Pain Reliever places the product squarely in the narrow space between temporary symptom control and the need for prompt dental evaluation. The gel is positioned as a topical oral remedy for minor tooth and gum injuries, with a use case limited to short-term relief rather than ongoing management. Its active ingredients are benzalkonium chloride 0.13%, benzocaine 20%, menthol 0.26%, and zinc chloride 0.15%, a combination designed for local oral application in a white, mint-flavored gel.
One sentence on the label carries more clinical weight than the rest: methemoglobinemia is a serious risk.
That warning matters because benzocaine, a topical anesthetic, can oxidize hemoglobin and impair oxygen delivery even when the product has been used before without incident. The label makes clear that the reaction can occur after prior tolerated exposure, which is a reminder that repeat use does not confer safety in susceptible patients. In practical terms, a patient seeking relief for an irritated gum or toothache may actually be masking a problem that requires dental treatment, while simultaneously exposing themselves to a rare but potentially life-threatening oxygen transport disorder.
Benzocaine drives the analgesic effect, while the label limits duration and age of use
The product’s stated purpose is straightforward: temporary relief of pain caused by minor oral and gum injuries, first aid to help prevent infection from minor oral irritations, and support for loose teeth and dental health. The inclusion of benzocaine 20% explains the numbing effect, while benzalkonium chloride, menthol, and zinc chloride contribute the antiseptic and oral-care profile described on the label. This is a topical product, not a systemic therapy, and the directions reflect that narrow scope.
Adults and children 2 years of age and over may apply the gel to the affected area up to four times daily, or as directed by a dentist or doctor. Children between 2 and 12 years of age should only use it under physician supervision, and children under 2 years of age should not use it. The label also warns not to exceed the recommended dosage for more than 7 days unless directed by a dentist or doctor, and it specifically frames the preparation as a temporary expedient until a dentist can be consulted. Avoiding toothpaste or soft drinks or fruit juices for at least one hour after application suggests an effort to preserve local contact time and reduce immediate washout.
The safety logic is clinical as much as pharmaceutical. Oral pain often drives patients to overuse fast-acting topical agents because relief arrives before the underlying cause is addressed. In a setting of caries, periodontal irritation, mucosal trauma, or eruptive discomfort, the gel can blunt symptoms without altering the disease process beneath it. The label’s short-duration language is a boundary line, not a suggestion.
Cyanosis, dyspnea, and fatigue are the warning signs that should stop use immediately
The stop-use instructions are unusually direct and deserve equal attention to the dosing guidance. Pale, gray, or blue colored skin; headache; rapid heart rate; shortness of breath; dizziness or lightheadedness; fatigue or lack of energy; sore mouth symptoms that do not improve in 7 days; swelling, rash, fever; or irritation, pain, and redness that persist or worsen all require immediate medical attention or clinician review. For a parent or caregiver, the appearance of cyanosis in a child after oral benzocaine exposure is a particularly urgent red flag.
These instructions align with the mechanism of methemoglobinemia. When methemoglobin rises, the blood loses effective oxygen-carrying capacity, and the bedside picture can shift quickly from routine oral discomfort to a hypoxic emergency. The label does not present that complication as theoretical. It frames the condition as serious and treatment-requiring, which is the right level of caution for a product that can be used at home without direct supervision in adults.
The label also states that use should stop and a doctor should be consulted if the mouth symptoms do not improve in 7 days. Persistent symptoms raise the possibility that the pain source is not a minor irritation at all, but a dental lesion, infection, or injury that needs diagnosis rather than repeated topical numbing.
Ingredient selection and packaging reflect an OTC product built for brief use
The inactive ingredient list includes polyethylene glycol 300, polyethylene glycol 3000, saccharin sodium, sorbic acid, cinnamon, salt substitute, Schisandra chinensis seed, and Cyperus rotundus fruit. The formulation is presented as a 10 mL tube in a single-package configuration, with marketing information identifying it as an OTC monograph drug under M022. The product is labeled for topical administration and carries no DEA schedule.
Manufacturing and distribution details are also spelled out clearly. Zhejiang Jingwei Pharmaceutical Co., Ltd. in Changshan Industrial Park, Zhejiang, China, manufactures the product, and Kungpo Health Care & Herbal Center Inc. in Ontario, California, is listed as the importer and distributor. The label update date is October 16, 2026, and the package identification includes NDC 87351-761-10.
In this kind of label, the most important clinical message is often not the brand name or the flavor profile. It is the boundary between an appropriate temporary oral anesthetic and a scenario in which an oral complaint needs dental or medical evaluation. A topical anesthetic can quiet pain fast, but it cannot distinguish a toothache from an evolving lesion, and it cannot make an unsafe dose safe.
What the label asks clinicians and caregivers to remember
The risk-benefit profile is narrow and explicit. ORA YOGU 4X is intended for temporary relief of minor oral and gum pain, with limited dosing frequency, a short use window, and age-based restrictions. The methemoglobinemia warning should remain front and center whenever benzocaine products are used, especially in young children or in anyone with symptoms suggestive of impaired oxygenation.
The label leaves no ambiguity about the next step when pain persists: consult a dentist or doctor rather than extending use. In oral health, a temporary numbing gel can buy time, but it should never become the treatment plan.
The product’s own instructions set the ceiling on its role, and that ceiling is low: brief symptom control, not ongoing management of dental disease.